Brief: HUTCHMED (China) Says NDA Acceptance In China For Fruquintinib Combination With Sintilimab
05/06/2025 24:47
June 5 (Reuters) - HUTCHMED (China) Ltd 0013.HK: NDA ACCEPTANCE IN CHINA FOR FRUQUINTINIB COMBINATION WITH SINTILIMAB ACCEPTED FOR REVIEW BY CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION Source text: ID:nHKS3DXz2 Further company coverage: 0013.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on HUTCHMED (China)
See all newsKras: EGFR-Antibody licensing deal with GSK closes
Brief: Hutchmed (China) Closes Exclusive Development And License Agreement With GSK Unit
Factbox: Major drugmakers turn to China for licensing deals
Factbox: Major drugmakers turn to China for licensing deals
Factbox: Major drugmakers turn to China for licensing deals